{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:46:26Z","timestamp":1768319186873,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Youth Scientific Research Training Project of GZUCM","award":["2019QNPY02"],"award-info":[{"award-number":["2019QNPY02"]}]},{"name":"Young Top Talent Project of Scientific and Technological Innovation in Special Support Plan for Training High-level Talents in Guangdong","award":["2017TQ04R627"],"award-info":[{"award-number":["2017TQ04R627"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81873375"],"award-info":[{"award-number":["81873375"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>This article aims to summarize the key characteristics of registered trials of 2019 novel coronavirus (COVID-19), in terms of their spatial and temporal distributions, types of design and interventions, and patient characteristics among others.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A comprehensive search of the registered COVID-19 trials has been performed on platforms including ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (WHO ICTRP), Chinese Clinical Trials Registry (CHiCTR), Australian Clinical Trials Registry, Britain\u2019s National Research Register (BNRR), Current Control Trials (CCT), and Glaxo Smith Kline Register. Trials registered at the first 8\u00a0weeks of the COVID-19 outbreak are included, without language restrictions. For each study, the registration information, study design, and administrator information are collected and summarized.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 220 registered trials were evaluated as of February 27, 2020. Hospital-initiated trials were the majority and account for 80% of the sample. Among the trials, pilot studies and phase 4 trials are more common and represent 35% and 19.1% of the sample, respectively. The median sample size of the registered trials is 100, with interquartile range 60\u2013240. Further, 45.9% of the trials mentioned information on a data monitoring committee. 54.5% of the trials did not specify the disease severity among patients they intend to recruit. Four types of interventions are most common in the experimental groups across the registered studies: antiviral drugs, Traditional Chinese Medicine (TCM), biological agents, and hormone drugs. Among them, the TCM and biological agents are frequently used in pilot study and correspond to a variety of primary endpoints. In contrast, trials with antiviral drugs have more targeted primary outcomes such as \u201cCOVID-19 nucleic acid test\u201d and \u201c28-day mortality.\u201d<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>We provide an evidence mapping and analysis of registered COVID-19 clinical trials in China. In particular, it is critical for ongoing and future studies to refine their research hypothesis and better identify their intervention therapies and the corresponding primary outcomes. It is also imperative for multiple public health divisions and research institutions to work together for integrative clinical data capture and sharing, with a common objective of improving future studies that evaluate COVID-19 interventions.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12916-020-01612-y","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T14:35:04Z","timestamp":1591194904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["An evidence mapping and analysis of registered COVID-19 clinical trials in China"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7821-4699","authenticated-orcid":false,"given":"Liming","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuqi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingchun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunzhi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nenggui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"key":"1612_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506.","journal-title":"Lancet"},{"key":"1612_CR2","doi-asserted-by":"crossref","unstructured":"Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020; [Epub ahead of print].","DOI":"10.1016\/S0140-6736(20)30260-9"},{"key":"1612_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"JF Chan","year":"2020","unstructured":"Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514\u201323.","journal-title":"Lancet."},{"key":"1612_CR4","unstructured":"WHO. WHO Director-General\u2019s remarks at the media briefing on 2019-nCoV on 11 February 2020. https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed 22 Feb 2020)."},{"key":"1612_CR5","unstructured":"People's Daily. The real-time dynamic monitoring data of 2019nCoV1 in China. http:\/\/health.people.com.cn\/GB\/26466\/431463\/431576\/index.html (Accessed 22 Feb 2020)."},{"key":"1612_CR6","unstructured":"WHO. Coronavirus disease (COVID-2019) situation reports. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports\/ (accessed Feb 22, 2020)."},{"key":"1612_CR7","unstructured":"WHO. World experts and funders set priorities for COVID-19 research. https:\/\/www.who.int\/news-room\/detail\/12-02-2020-world-experts-and-funders-set-priorities-for-covid-19-research (accessed Feb 22, 2020)."},{"key":"1612_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/1740774515620612","volume":"13","author":"M Nason","year":"2016","unstructured":"Nason M. Statistics and logistics: design of Ebola vaccine trials in West Africa. Clin Trials. 2016;13:87\u201391.","journal-title":"Clin Trials"},{"key":"1612_CR9","unstructured":"The Central People\u2019s Government of the People\u2019s Republic of China. Notice on printing and distributing Diagnosis and Treatment Guideline of COVID-19 (Version 6) of China. http:\/\/www.gov.cn\/zhengce\/zhengceku\/2020-02\/19\/content_5480948.htm (Accessed 22 Feb 2020)."},{"key":"1612_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/d41586-020-00444-3","volume":"578","author":"A Maxmen","year":"2020","unstructured":"Maxmen A. More than 80 clinical trials launch to test coronavirus treatments. Nature. 2020;578:347\u20138.","journal-title":"Nature."},{"key":"1612_CR11","unstructured":"People\u2019s Daily. Several drugs against COVID-19 already in clinical trials: official. http:\/\/en.people.cn\/n3\/2020\/0216\/c90000-9658261.html (Accessed 22 Feb 2020)."},{"key":"1612_CR12","doi-asserted-by":"publisher","first-page":"k1614","DOI":"10.1136\/bmj.k1614","volume":"363","author":"K Hemming","year":"2018","unstructured":"Hemming K, Taljaard M, McKenzie JE, et al. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614.","journal-title":"BMJ."},{"key":"1612_CR13","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2105\/AJPH.2017.303706","volume":"107","author":"EL Turner","year":"2017","unstructured":"Turner EL, Li F, Gallis JA, et al. Review of recent methodological developments in group-randomized trials: part 1-design. Am J Public Health. 2017;107:907\u201315.","journal-title":"Am J Public Health"},{"key":"1612_CR14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.2105\/AJPH.2017.303707","volume":"107","author":"EL Turner","year":"2017","unstructured":"Turner EL, Prague M, Gallis JA, et al. Review of recent methodological developments in group-randomized trials: part 2-analysis. Am J Public Health. 2017;107:1078\u201386.","journal-title":"Am J Public Health"},{"key":"1612_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13063-018-3116-3","volume":"20","author":"K Hemming","year":"2019","unstructured":"Hemming K, Taljaard M, Grimshaw J. Introducing the new CONSORT extension for stepped-wedge cluster randomised trials. Trials. 2019;20:68.","journal-title":"Trials."},{"issue":"2","key":"1612_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cct.2006.05.007","volume":"28","author":"MA Hussey","year":"2007","unstructured":"Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials. 2007;28(2):182\u201391.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"1612_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12916-016-0760-x","volume":"14","author":"AM Rojek","year":"2016","unstructured":"Rojek AM, Horby PW. Modernising epidemic science: enabling patient-centred research during epidemics. BMC Med. 2016;14(1):212.","journal-title":"BMC Med"},{"issue":"9","key":"1612_CR18","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/cid\/cix1061","volume":"66","author":"AM Rojek","year":"2018","unstructured":"Rojek AM, Dunning J, Leliogdowicz A, et al. Regulatory and operational complexities of conducting a clinical treatment trial during an Ebola virus disease epidemic. Clin Infect Dis. 2018;66(9):1454\u20137.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1612_CR19","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.3201\/eid2511.180628","volume":"25","author":"ND Kayem","year":"2019","unstructured":"Kayem ND, Rojek A, Denis E, et al. Clinical REsearch During Outbreaks (CREDO) training for low- and middle-income countries. Emerg Infect Dis. 2019;25(11):2084\u20137.","journal-title":"Emerg Infect Dis"},{"key":"1612_CR20","unstructured":"XINHUANET. Various approaches adopted in vaccine development for COVID-19: official. http:\/\/www.xinhuanet.com\/english\/2020-02\/15\/c_138786931.htm (Accessed 22 Feb 2020)."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-020-01612-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T23:51:34Z","timestamp":1622505094000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01612-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1186\/s12916-020-01612-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"2 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Only openly available data was used in this study. Ethical approval was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}